CNS Pharmaceuticals Inc
CNSP
Company Profile
Business description
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
Contact
2100 West Loop South
Suite 900
HoustonTX77027
USAT: +1 800 946-9185
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
8
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.90 | 25.20 | -0.28% |
| CAC 40 | 8,258.26 | 142.51 | 1.76% |
| DAX 40 | 25,389.10 | 500.54 | 2.01% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,734.42 | 128.39 | 0.50% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 65,077.21 | 80.98 | -0.12% |
| NZX 50 Index | 13,061.01 | 90.73 | 0.70% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,656.90 | 19.70 | -0.23% |
| SSE Composite Index | 4,117.85 | 34.72 | -0.84% |